extrinsic pathway

The extrinsic pathway begins when vascular injury exposes tissue factor (TF, Factor III), which is expressed on subendothelial cells and released upon trauma. TF binds circulating Factor VIIa (and VII, which is autoactivated) to form the TF-VIIa complex in the presence of calcium. This complex activates Factor X to Xa, which then converges with the intrinsic pathway at the common pathway. Factor Xa, with Factor Va, calcium, and phospholipids, forms the prothrombinase complex that converts prothrombin (II) to thrombin (IIa), which cleaves fibrinogen to fibrin, stabilizing the clot (further cross-linked by Factor XIIIa).

The extrinsic pathway is considered the primary physiological initiator of coagulation in vivo (more important than the intrinsic pathway), providing a rapid burst of thrombin generation immediately after vessel injury. It is clinically assessed via the Prothrombin Time (PT), often standardized as the International Normalized Ratio (INR).

Clinical correlations: - Warfarin inhibits vitamin K–dependent factors (II, VII, IX, X, and proteins C/S); Factor VII has the shortest half-life, so PT/INR is most sensitive to warfarin's early effect and used to monitor therapy. - Liver disease also prolongs PT since Factor VII (extrinsic pathway) has a short half-life and is synthesized in the liver, making PT/INR a sensitive marker of hepatic synthetic dysfunction. - Factor VII deficiency (rare) prolongs PT with normal PTT. - Disseminated intravascular coagulation (DIC) is triggered by widespread tissue factor exposure, activating the extrinsic pathway and consuming clotting factors and platelets.

Understanding the extrinsic pathway is essential for interpreting coagulation studies, differentiating bleeding disorders, and understanding pharmacologic anticoagulation (e.g., warfarin monitoring via PT/INR) versus the intrinsic pathway (PTT, heparin monitoring).